Salubris Pharma

4 articles about Salubris Pharma

• D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China

  9/27/2021

  D&D will receive an upfront payment of $4 million and is eligible to receive additional undisclosed milestone payments upon achievement of certain development and commercial milestones

• 

  5-Member GO Therapeutics Inks $195 Million Deal with Roche

  10/2/2018

  GO Therapeutics, headquartered in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.

• Salubris Pharma Invests $5 Million in Boston's GO Therapeutics

  9/27/2017

• Chinese Pharmaceutical Giant Salubris Pharma Gets Exclusive Worldwide Rights to a New Liver Cancer Drug

  8/9/2017